# PODD — Insulet Corporation

## Company & Research Metadata

- **Company:** Insulet Corporation
- **Ticker:** PODD
- **Exchange:** Nasdaq
- **Sector / Industry:** Health Care / automated insulin delivery
- **Template version:** 2.7
- **Research date:** 2026-10-21
- **Valuation / score price snapshot:** $154.86 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Primary operating period reviewed:** Q2 2026
- **Historical period reviewed:** TTM, FY 2025, FY 2024; latest balance-sheet date shown below
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q2 2026, complete material Q&A
- **Latest post-earnings management commentary reviewed:** No separate later management presentation incorporated

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 9 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $154.86 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $57.65 / $159.44 / $290.41 |
| Scenario Probabilities | 25% / 50% / 25% |
| Probability-Weighted Fair Value | $166.74 |
| Probability-Weighted Expected Return | +7.7% |
| Bear-Case Return | -62.8% |
| Strong Buy Zone | ≤ $63.42 |
| Buy Zone | >$63.42–$133.39 |
| Avoid Chasing Above | > $185.27 |
| Quality Score / Tier | 83.4 / Tier A |
| Opportunity Score / Rank | 56.1 / #34 of 76 |
| Risk Level | Medium-High |
| Tracking / Ownership | Primary Watchlist / Not Owned |

**Decision rationale:** PODD is **Hold / Watch** at $142.64, with +16.9% probability-weighted upside and -59.6% bear-case return. A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. Confidence is 55/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

## Investment Thesis

A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. Q2 revenue rose 23.5% to $801.7 million, including strong international growth. The key question is whether new-patient adoption, retention and manufacturing scale sustain attractive margins as competition increases. The lower market valuation improves the entry case, provided the operating thesis remains intact. The latest call exposed weaker Type 2 retention, rather than merely slightly lower utilization. Management's revised guidance assumes those trends persist through the second half. Faster new-patient starts cannot compensate indefinitely for patients leaving treatment.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| New-patient starts and retention | A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. |
| Reimbursement, competition and product reliability | New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value. |
| Manufacturing scale and cash conversion | Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. |

## Business Overview

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. Automated delivery integrates with compatible glucose-monitoring technology and software. Pharmacy distribution, reimbursement, clinical support and patient training shape access. U.S. and international adoption have different pricing and reimbursement economics.

### Business Takeaway

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.

## Industry, TAM & Market Share

Insulin-treated diabetes provides a meaningful runway, including patients who have not used pumps. Clinical eligibility, reimbursement, patient preference and training constrain the economically reachable market. Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Tandem (TNDM) | Direct: insulin pumps and automated insulin delivery | Product scope; no matched operating-scale series | Competes for pump starts and renewals | Customer choice in the stated segment only |
| Beta Bionics (BBNX) | Direct: iLet automated insulin delivery | Product scope; no matched operating-scale series | Competes for AID patient adoption | Customer choice in the stated segment only |
| MiniMed (MMED) | Direct: MiniMed automated insulin-delivery systems | Product scope; no matched operating-scale series | Competes for AID patients | Customer choice in the stated segment only |
| Multiple daily injections | Substitute: insulin pens/syringes, often with CGM | Product scope; no matched operating-scale series | Patient preference and access affect substitution | Customer choice in the stated segment only |

### Industry Takeaway

Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence. The base case requires evidence of profitable adoption within that market.

## Customer Economics

New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value. Recurring consumables produce attractive visibility after adoption. Customer service, acquisition spending and geographic mix must be included when evaluating incremental margins.

### Customer-Economics Takeaway

The economic test is Manufacturing scale and cash conversion. Customer service, acquisition spending and geographic mix must be included when evaluating incremental margins.

## Competitive Landscape & Moat

### Competitive Landscape

Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Tandem (TNDM) | No consistent comparable series | Direct: insulin pumps and automated insulin delivery | Established pump/algorithm ecosystem | Tubed/tubeless workflows and distribution differ | Competes for pump starts and renewals |
| Beta Bionics (BBNX) | No consistent comparable series | Direct: iLet automated insulin delivery | Distinct automation proposition | Different device workflow and commercial scale | Competes for AID patient adoption |
| MiniMed (MMED) | No consistent comparable series | Direct: MiniMed automated insulin-delivery systems | Pump, sensor and consumables ecosystem | Independent after Medtronic separation; distinct tubed workflow | Competes for AID patients |
| Multiple daily injections | No consistent comparable series | Substitute: insulin pens/syringes, often with CGM | Familiar treatment and no pump attachment | Does not provide the same automated delivery workflow | Patient preference and access affect substitution |

### Moat Assessment

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. Competition can still improve convenience or pricing. The moat depends on maintaining reliability and patient outcomes.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2024 | 2,072 | 22.07% | 69.79% | 14.91% | 305.3 | 14.74% | 69.3 | 74 | 958.8 | 1,434 |
| FY2025 | 2,708 | 30.73% | 71.63% | 17.50% | 377.7 | 13.95% | 62.7 | 72 | 716.1 | 1,003 |
| Q1 FY2026 | $761.7 | N/D | 69.5% | 16.0% | $89.5 (derived: CFO - capex) | 11.8% | $21.3 | 70.202 | N/D | N/D |
| Q2 FY2026 | $801.7 | N/D | 70.2% | 16.2% | $55.9 (derived: current YTD - prior YTD) | 7.0% | $19.6 (derived: current YTD - prior YTD) | 69.403 | N/D | N/D |
| H1 FY2026 | $1,563.4 | N/D | 69.8% | 16.1% | $145.4 (derived: CFO - capex) | 9.3% | $40.9 | 69.803 | N/D | N/D |
| Q3 FY2026 | $842 | N/D | 75.1% | 22.5% | $66.4 (derived: current YTD - prior YTD) | 7.9% | $20.6 (derived: current YTD - prior YTD) | 69.492 | N/D | N/D |
| 9M FY2026 | $2,405.4 | N/D | 71.7% | 18.4% | $211.8 (derived: CFO - capex) | 8.8% | $61.5 | 69.699 | N/D | N/D |

### Financial Takeaways

Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. TTM FCF was about $294 million and SBC $78 million. The model assumes meaningful further scale but includes compensation and ongoing manufacturing investment. Growth should be assessed against cash conversion and product quality, not only adjusted EPS.

**Financial direction:** Mixed — assess the reported trend alongside dilution and the balance sheet.

## Management & Capital Allocation

Management has expanded adoption and international reach. Capital allocation should prioritize manufacturing reliability, patient experience and profitable access. Monitor capacity investment, quality events and the consistency of new-product execution. Management has not yet demonstrated that Type 2 service interventions restore retention. Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

### Management Takeaway

Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $154.86 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $9.89B |
| Enterprise Value | $10.31B |
| Trailing P/E | 26.93 |
| Provider forward P/E | 20.66 |
| EV / Sales | 3.38 |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| PODD — Insulet Corporation | Subject company | Public | 20.66 | 3.38 | automated insulin delivery; 3Y revenue-growth estimate 15.98%; operating margin 16.89% |
| BBNX — Beta Bionics | Direct iLet AID competitor | Public | n/a | 6.50 | automated insulin delivery; 3Y revenue-growth estimate 39.09%; operating margin -69.75% |
| TNDM — Tandem | Direct pump/AID competitor | Public | n/a | 1.38 | insulin pump systems; 3Y revenue-growth estimate 10.27%; operating margin -4.13% |
| MiniMed (MMED) | Direct: MiniMed automated insulin-delivery systems | Public | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes for AID patients |
| Multiple daily injections | Substitute: insulin pens/syringes, often with CGM | Operating alternative / no standalone security | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Patient preference and access affect substitution |

**Comparable takeaway:** Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 28×, versus the provider's current forward P/E of 20.66×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of **$117.64**, versus the central base FV of **$159.44**. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 3Y revenue CAGR 10%; sustainable 2029 EPS $4.50 after compensation; 18× P/E; 12% discount rate; Slower adoption and continued costs produce $4.50 of 2029 sustainable EPS. | $57.65 | 25% | Execution, financing or competitive setbacks remain credible | -62.8% |
| Base | 3Y revenue CAGR 18%; sustainable 2029 EPS $8.00 after compensation; 28× P/E; 12% discount rate; The central revenue and margin trajectory produces $8.00 of 2029 sustainable EPS. | $159.44 | 50% | Most likely operating trajectory, requiring measurable progress | +3.0% |
| Bull | 3Y revenue CAGR 25%; sustainable 2029 EPS $12.00 after compensation; 34× P/E; 12% discount rate; Strong adoption and mature margins produce $12.00 of 2029 sustainable EPS. | $290.41 | 25% | Successful product conversion and operating leverage; not assured | +87.5% |
| **Probability-Weighted** | Sum of each scenario value × its probability | $166.74 | **100%** | Judgmental scenario probabilities | +7.7% |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
- **Cross-check methods:** Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in [the valuation workpaper](../valuation/watchlist_models_2026-10-21.md).
- **Key valuation dependencies:** New-patient starts and retention; Reimbursement, competition and product reliability; Manufacturing scale and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
- **Valuation confidence / Risk Level:** 55/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
- **Margin-of-safety conclusion:** Hold / Watch at $142.64. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

## Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Robbie Marcus / J.P. Morgan | How does deterioration in Type 2 retention affect guidance? | Management said guidance assumes the retention pressure persists. | Confirm that this opportunity converts into profitable recurring demand. |
| Travis Steed / Bank of America | What supports confidence in the reduced outlook? | Management said diversified growth supports that outlook. | Treat the stated timetable as conditional on demonstrated execution. |
| Larry Biegelsen / Wells Fargo | What matters most to improving retention? | Management emphasized early patient support and primary-care access. | Check repeat usage and cohort economics rather than initial sales alone. |
| Jeff Johnson / Baird | How do adherence initiatives interact with payer access? | Management said it is not pursuing an exclusionary access strategy. | Confirm that this opportunity converts into profitable recurring demand. |
| Matt Taylor / Jefferies | What evidence supports the retention initiatives? | Management said early evidence is encouraging but does not establish broad improvement. | Check repeat usage and cohort economics rather than initial sales alone. |
| Marie Thibault / BTIG | Does guidance assume a recovery in retention despite competition? | Management said guidance does not assume a retention recovery. | Treat the stated timetable as conditional on demonstrated execution. |
| Richard Newitter / Truist Securities | When could the interventions affect results? | Management said second-half assumptions remain cautious. | Treat the stated timetable as conditional on demonstrated execution. |
| Joe Federico / Stifel | How do acquisition and service initiatives affect costs? | Management said the initiatives fit within the existing cost baseline. | Require durable cash conversion after compensation and ongoing investment. |
| Kieran Ryan / Deutsche Bank | Is retention or utilization the larger source of variance? | Management said retention is the larger source of variance. | Check repeat usage and cohort economics rather than initial sales alone. |

### Analyst-Q&A Takeaway

Type 2 retention is the central admission, and guidance assumes it does not recover this year. Patient-support initiatives need measured cohort improvement before the broader addressable market deserves full credit.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| New-patient starts and retention | A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. | Revenue trajectory sustains approximately 18% annual growth on a comparable basis | Growth remains below the 10% bear assumption over a full operating cycle | Revenue outlook and scenario probabilities |
| Reimbursement, competition and product reliability | New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value. | After-cost earnings progress toward the base implied net margin of 11.2% | Competition, credit losses or service costs make that margin trajectory unattainable | Margins, moat score and valuation multiple |
| Manufacturing scale and cash conversion | Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. | Financing and compensation remain consistent with 70.4M economic shares in the 2029 base case | Required capital or cumulative dilution materially exceeds the model without matching earnings | Financial score, confidence and downside value |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 90 | 25% | 22.5 | New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value. |
| Moat and competitive position | 86 | 25% | 21.5 | Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. |
| Growth runway and durability | 82 | 20% | 16.4 | Insulin-treated diabetes provides a meaningful runway, including patients who have not used pumps. |
| Financial quality and balance sheet | 79 | 15% | 11.9 | Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. |
| Management, governance and capital allocation | 74 | 15% | 11.1 | Management has expanded adoption and international reach. |
| **Quality Score** | **83.4** | **100%** | **83.4** | Weighted score, independent of ownership and current price |

- **Quality Tier:** A
- **Speculative override:** None

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 83.4 | 83.4 | 30% | 25.0 |
| Probability-weighted upside | +7.7% | 65.3 | 35% | 22.9 |
| Bear-case downside | -62.8% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 55 | 55.0 | 15% | 8.3 |
| **Opportunity Score** |  | **56.1** | **100%** | **56.1** |

- **Opportunity Rank:** #34 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $142.64 | Hold / Watch | Hold / Watch | >$63.42–$133.39 | ≤ $63.42 | > $185.27 | $159.44 | $166.74 | +16.9% | 83.4 | 62.6 / #18 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [Insulet Corporation - Insulet Reports Second Quarter 2026 Results](https://investors.insulet.com/news/news-details/2026/Insulet-Reports-Second-Quarter-2026-Results/default.aspx) | Company IR / earnings filing | Q2 2026 | Latest operating results, guidance, products and financial supplement |
| [PODD complete earnings-call transcript](https://stockanalysis.com/stocks/podd/transcripts/661305-q2-2026/) | Transcript | Q2 2026 | Prepared remarks and all material Q&A exchanges |
| [PODD regular-session historical price](https://stockanalysis.com/stocks/podd/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [PODD valuation statistics](https://stockanalysis.com/stocks/podd/statistics/) | Market data | 2026-10-20 close; ratios retrieved 2026-10-21 | Market capitalization, shares, quoted multiples and current ratios |
| [PODD historical income statement](https://stockanalysis.com/stocks/podd/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [PODD historical balance sheet](https://stockanalysis.com/stocks/podd/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [PODD historical cash flows](https://stockanalysis.com/stocks/podd/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Beta Bionics statistics](https://stockanalysis.com/stocks/bbnx/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [Tandem statistics](https://stockanalysis.com/stocks/tndm/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [MiniMed separation prospectus — standalone products and competition](https://www.sec.gov/Archives/edgar/data/2062583/000162828026064932/minimedgroupinc-424b3.htm) | Regulatory filing / primary product evidence | 2026 separation prospectus; checked 2026-10-28 | Independent MiniMed, AID systems and separation from Medtronic |
| [SEC XBRL company facts — PODD](https://data.sec.gov/api/xbrl/companyfacts/CIK0001145197.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |